Thomas Davis, MD
Hematology & Oncology · Jacksonville, FLNPI 1710982822
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.7%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Johnson & Johnson at 40.3% of the total. Reporting peaked in 2019 at $3,941 and has fallen 92.4% since, to $300 in 2025.
Across 155 payments — averaging $58.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$4K
- Verastem, Inc.$1K
- E.r. Squibb & Sons, L.L.C.$1K
- CTI Biopharma Corp.$1K
- Pfizer$437
- Novartis$203
- plus $1K from 26 others
Across 3 payments — averaging $19,060 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$57K
What the payments were for
- Consulting fees$5,30959%
- Speaking & faculty fees$1,00011%
- Travel & lodging$4975%
- Food & beverage$2,16824%
- Education$741%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 30 | $3,643 |
| Verastem, Inc. | 1 | $1,320 |
| E.r. Squibb & Sons, L.L.C. | 2 | $1,234 |
| CTI Biopharma Corp. | 2 | $1,015 |
| Pfizer | 36 | $437 |
| Novartis | 12 | $203 |
| Astellas Pharma US Inc | 9 | $134 |
| Eisai Inc. | 6 | $84 |
| Merck | 4 | $80 |
| Sanofi | 5 | $79 |
| Genentech USA, Inc. | 5 | $78 |
| Janssen Scientific Affairs, LLC | 3 | $72 |
| Taiho Oncology, Inc. | 4 | $71 |
| Incyte Corporation | 3 | $50 |
| AstraZeneca(2 entities) | 3 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $47 |
| Daiichi Sankyo Inc. | 3 | $47 |
| Tempus AI, Inc | 2 | $47 |
| Boehringer Ingelheim | 3 | $43 |
| Foundation Medicine, Inc. | 1 | $40 |
| Aurobindo Pharma USA, Inc. | 3 | $38 |
| Array Biopharma Inc | 2 | $36 |
| EMD Serono, Inc. | 2 | $31 |
| Mirati Therapeutics, Inc. | 2 | $29 |
| TG Therapeutics, Inc. | 1 | $26 |
| AMAG Pharmaceuticals, Inc. | 2 | $26 |
| Gilead | 2 | $24 |
| Sobi, Inc | 1 | $17 |
| Bayer | 1 | $14 |
| Global Blood Therapeutics, Inc. | 1 | $13 |
| Karyopharm Therapeutics Inc. | 1 | $12 |
| Tesaro, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,049 in reported general payments places this provider in the 60th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 30 | $484,804 |
| JakafiRuxolitinib Phosphate | 21 | $362,670 |
| PomalystPomalidomide | 16 | $359,500 |
| CabometyxCabozantinib S-Malate | 11 | $266,594 |
| IbrancePalbociclib | 14 | $222,142 |
| TazverikTazemetostat Hydrobromide | 11 | $221,661 |
| CalquenceAcalabrutinib Maleate | 12 | $214,614 |
| RevlimidLenalidomide | 11 | $185,652 |
| EliquisApixaban | 60 | $78,642 |
| XareltoRivaroxaban | 33 | $38,028 |
| Enoxaparin Sodium | 13 | $7,423 |
| Anastrozole | 100 | $2,576 |
| Oxycodone Hcl | 78 | $1,648 |
| SpsSodium Polystyrene Sulfon/Sorb | 27 | $1,354 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 47 | $1,350 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $50 | $362,67021 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $1,234 | $359,50016 claims |
| PfizerIbrance, Eliquis | $437 | $300,78474 claims |
| AstraZenecaCalquence | $48 | $214,61412 claims |
| Johnson & JohnsonXarelto | $3,643 | $38,02833 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Jacksonville
- Edith PerezJacksonville$1.1M
- Vamsidhar VelchetiJacksonville$966K
- Arnab BasuJacksonville$440K
- Sikander AilawadhiJacksonville$179K
- James ForanJacksonville$164K
- Asher Chanan KhanJacksonville$109K
- Martin DietrichRockledge$6.2M
- Mark SocinskiOrlando$2.4M
- Tarek MekhailOrlando$2.2M
- Edgardo SantosFort Lauderdale$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.